No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AVTX Avalo Therapeutics
- 12.2100
- +0.5800+4.99%
Close Apr 22 16:00 ET
- 12.6600
- +0.4500+3.69%
Pre 08:49 ET
12.63MMarket Cap-107P/E (TTM)
13.3700High11.4600Low83.47KVolume11.4600Open11.6300Pre Close1.04MTurnover9.08%Turnover RatioLossP/E (Static)1.03MShares1130.400052wk High1.73P/B11.22MFloat Cap3.950152wk Low--Dividend TTM919.32KShs Float22031.7120Historical High--Div YieldTTM16.42%Amplitude3.9501Historical Low12.4650Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.
Express News | Avalo Therapeutics Shares Are Trading Higher After Oppenheimer Upgraded the Stock From Perform to Outperform and Announced a $35 Price Target
Express News | Avalo Therapeutics Shares up 6.0% Premarket After Oppenheimer Raises to Outperform From Perform
Express News | Avalo Therapeutics : Oppenheimer Raises to Outperform From Perform
Express News | Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target
Avalo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 118.07% Oppenheimer → $35 Upgrades Perform → Outperform 06/27/2023 — Oppenheimer Downgrades Ou
Comments
$Avalo Therapeutics(AVTX.US$ worth to buy some?
1
$Avalo Therapeutics(AVTX.US$ small push at open
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg